SCHEMBL1534068

SCHEMBL1534068

CCOC(=O)c1c(OC)ccc(Br)c1C

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 6/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
MAPT P10636 5/20 0.49
MEN1 O00255 3/20 0.49
KMT2A Q03164 3/20 0.49
ALDH1A1 P00352 3/20 0.49
ALOX15 P16050 2/20 0.49
USP2 O75604 1/20 0.49
SMN1; SMN2 Q16637 3/20 0.48
GAA P10253 2/20 0.47
TSHR P16473 1/20 0.47
CA12 O43570 1/20 0.46
CA1 P00915 1/20 0.46
CA2 P00918 1/20 0.46
CA7 P43166 1/20 0.46
CA9 Q16790 1/20 0.46
CA14 Q9ULX7 1/20 0.46
HSD17B2 P37059 1/20 0.45
TUBB4A P04350 1/20 0.45
TUBB P07437 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3973107 0.85 ERN1 (0.45) MAPTALDH1A1CA12CA1CA2
SCHEMBL7522484 0.84 LMNA (0.48) LMNAL3MBTL1MAPTMEN1KMT2A
SCHEMBL31502538 0.83 LMNA (0.47) LMNAL3MBTL1MAPTMEN1KMT2A
SCHEMBL17091203 0.83 LMNA (0.47) LMNAL3MBTL1MAPTMEN1KMT2A
SCHEMBL11922986 0.82 MAPT (0.44) LMNAL3MBTL1MAPTMEN1KMT2A
SCHEMBL26493679 0.81 CA12 (0.50) MAPTMEN1KMT2AALDH1A1ALOX15
SCHEMBL22980480 0.81 LMNA (0.48) LMNAL3MBTL1MAPTMEN1KMT2A
SCHEMBL15729532 0.81 PRKCZ (0.50) LMNAMAPTALDH1A1SMN1; SMN2GAA
SCHEMBL16041589 0.81 CA12 (0.54) LMNAL3MBTL1MAPTMEN1KMT2A
SCHEMBL6905553 0.81 ALDH1A1 (0.50) LMNAMAPTMEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119462608-A Fused ring CYP11A1 inhibitors 轩竹生物科技股份有限公司 2025-02-18 CN disclosed
CN-111943823-A Preparation method of metrafenone 安徽工业大学 2020-11-17 CN disclosed
EP-3275861-A1 TETRACYCLINE COMPOUNDS Tetraphase Pharmaceuticals, Inc. (US) 2018-01-31 EP disclosed
US-20170334841-A1 TETRACYCLINE COMPOUNDS TETRAPHASE PHARMACEUTICALS, INC. 2017-11-23 US disclosed
US-20170334841-A1 TETRACYCLINE COMPOUNDS TETRAPHASE PHARMACEUTICALS, INC. 2017-11-23 US disclosed
US-20170334841-A1 TETRACYCLINE COMPOUNDS TETRAPHASE PHARMACEUTICALS, INC. 2017-11-23 US disclosed
EP-2470500-B1 TETRACYCLINE COMPOUNDS TETRAPHASE PHARMACEUTICALS INC (US) 2017-10-04 EP disclosed
EP-2470500-B1 TETRACYCLINE COMPOUNDS TETRAPHASE PHARMACEUTICALS INC (US) 2017-10-04 EP disclosed
US-9624166-B2 Tetracycline compounds TETRAPHASE PHARMACEUTICALS, INC. (US) 2017-04-18 US disclosed
US-9624166-B2 Tetracycline compounds TETRAPHASE PHARMACEUTICALS, INC. (US) 2017-04-18 US disclosed
CN-1495153-A 2-methoxy diphenyl ketone compound intermediate and its preparation method 2004-05-12 CN disclosed
CN-1147456-C Fungicidal 2-methoxybenzophenones 2004-04-28 CN disclosed
EP-1368343-A1 1-(2-METHOXYBENZYL)-3-BENZHYDRYLPIPERAZINES AS TACHYKININ ANTAGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-12-10 EP disclosed
WO-2002055518-A1 1-(2-METHOXYBENZYL)-3-BENZHYDRYLPIPERAZINES AS TACHYKININ ANTAGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-07-18 WO disclosed
EP-0897904-B1 Fungicidal 2-methoxybenzophenones BASF AG (DE) 2002-02-20 EP disclosed
US-6001883-A SUBSTITUTED BENZOPHENONES OF GIVEN FORMULA, SUCH AS 6,6'-DIMETHYL-2,2',3',4'-TETRAMETHOXY-5-TRIFLUOROMETHYL-BENZOPHENONE; HIGHLY SYSTEMIC FUNGICIDES; CONTROLLING FUNGAL DISEASE SUCH AS POWDERY MILDEW IN PLANTS AMERICAN CYANAMID COMPANY (US) 1999-12-14 US disclosed
US-5945567-A Fungicidal 2-methoxybenzophenones AMERICAN CYANAMID COMPANY (US) 1999-08-31 US disclosed
US-5922905-A INTERMEDIATES FOR FUNGICIDES AMERICAN CYANAMID COMPANY (US) 1999-07-13 US disclosed
CN-1217317-A Fungicidal 2-methoxybenzophenones AMERICAN CYANAMID CO (US) 1999-05-26 CN disclosed
EP-0897904-A1 Fungicidal 2-methoxybenzophenones American Cyanamid Company (US) 1999-02-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170334841-A1 TETRACYCLINE COMPOUNDS TUBB, TUBA1A, TUBA1C LMNA 3276/4885L3MBTL1 4735/4885MAPT 93/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.